Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pro Medicus Limited ( (AU:PME) ) has shared an announcement.
Pro Medicus Limited has notified the market of the issue of 47,930 unquoted performance rights under its employee incentive scheme, effective 3 September 2021. The move underscores the company’s continued use of equity-based remuneration to align staff and management interests with shareholders, potentially supporting employee retention and long-term value creation without immediately increasing the free float of tradable shares.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is an Australian healthcare technology company listed on the ASX, specialising in medical imaging IT solutions and radiology software used by hospitals, imaging centres and other healthcare providers. Its products support diagnostic imaging workflows and are aimed at improving clinical efficiency and patient care in both domestic and international markets.
Average Trading Volume: 172,710
Technical Sentiment Signal: Hold
Current Market Cap: A$21.96B
Learn more about PME stock on TipRanks’ Stock Analysis page.